Results 181 to 190 of about 226,969 (309)

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123. [PDF]

NPJ Breast Cancer
Gouveia MC, Barroso-Sousa R, Lapuchesky L, Testa L, Tavares MC, Balint FC, Dos Anjos CH, Gagliato DM, de Brito ML, Colucci G, Assad-Suzuki D, Rosa DD, Gomes NJB, Nunes NCC, de Sousa IM, Andrade MO, Madasi F, Bines J, Savignano M, Ferreira RDP, Santos CL, Tavares M, Monteiro MR, Souza ZS, Gomes AMU, Zucchetti BM, Ferrari A, Monteiro MMF, Signorini PA, Sanches S, Hoff PM, Paletta C, Estevez-Diz MDP, Bonadio RC.   +33 more
europepmc   +1 more source

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA. [PDF]

BMJ Open Respir Res
Mustapa MN, Hughes R, Jensen TJ, Dosanjh DP, Konstantinidis KV, Jonsson J, Nemes S, Jevnikar Z, Jones M, Adams A, Belvisi MG, Akuthota P, Kocks JWH.   +12 more
europepmc   +1 more source

Phenotyping patients with chronic obstructive pulmonary disease and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 900-911, April 2025.
Central illustration. Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin‐receptor‐neprilysin inhibitor; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular ...
Peter Moritz Becher, Felix Lindberg, Lina Benson, Camilla Hage, Ulf Dahlström, Stephan Rosenkranz, Francesco Cosentino, Giuseppe M.C. Rosano, Stefan Blankenberg, Paulus Kirchhof, Frieder Braunschweig, Lars H. Lund, Gianluigi Savarese   +12 more
wiley   +1 more source

Discovery of long-acting angiotensin 1-7, apelin-13, and bispecific mimetics for the treatment of cardiovascular and metabolic diseases

Journal of Molecular and Cellular Cardiology Plus
Weike Bao, Hannah Bolt, Nicholas Bhagroo, Kevin Minton, Fiona Shilliday, Ashot Sargsyan, Marie Persson, Elise Bernard, Petra Thulin, Pia Davidsson, Anders Cavallin, Claudio Colombo, Yasunori Aoki, Ulrik Jurva, Gabor Foldes, Liang Guo, Sarah Will, Regina Fritsche Danielson, Qing-Dong Wang, Kenny Hansson   +19 more
doaj   +1 more source

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia. [PDF]

ESMO Open
Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C, Bardia A.   +12 more
europepmc   +1 more source

Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization

ESC Heart Failure, Volume 12, Issue 2, Page 1227-1236, April 2025.
Comparative performance of 7 risk prediction indices in patients hospitalized for heart failure. In this cohort of 1206 patients, the LENT index offered the greatest discrimination, calibration, and overall accuracy in predicting 30‐day composite all‐cause mortality or readmission following hospitalization for heart failure.
Tauben Averbuch, Ali Zafari, Shofiqul Islam, Shun Fu Lee, Rajiv Sankaranarayanan, Stephen J Greene, Mamas A Mamas, Ambarish Pandey, Harriette GC Van Spall   +8 more
wiley   +1 more source

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study. [PDF]

Cancers (Basel)
Molica S, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Palma M, Arienti D, Mauro FR.   +37 more
europepmc   +1 more source

Molecular and immune biomarker testing in squamous-cell lung cancer: Effect of current and future therapies and technologies [PDF]

, 2018
Bradley, Jeffrey D, et al,
core   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source